Interspecies Variation of In Vitro Stability and Metabolic Diversity of YZG-331, a Promising Sedative-Hypnotic Compound

YZG-331, a synthetic adenosine derivative, express the sedative and hypnotic effects via binding to the adenosine receptor. The current study was taken to investigate the metabolic pathway of YZG-331 as well as species-specific differences in vitro. YZG-331 was reduced by 14, 11, 6, 46, and 11% with...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhihao Liu (Author), Yakun Yang (Author), Li Sheng (Author), Yan Li (Author)
Format: Book
Published: Frontiers Media S.A., 2017-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_2f5bea363c0944f0a0bcc70d9a446925
042 |a dc 
100 1 0 |a Zhihao Liu  |e author 
700 1 0 |a Zhihao Liu  |e author 
700 1 0 |a Yakun Yang  |e author 
700 1 0 |a Li Sheng  |e author 
700 1 0 |a Yan Li  |e author 
245 0 0 |a Interspecies Variation of In Vitro Stability and Metabolic Diversity of YZG-331, a Promising Sedative-Hypnotic Compound 
260 |b Frontiers Media S.A.,   |c 2017-08-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2017.00527 
520 |a YZG-331, a synthetic adenosine derivative, express the sedative and hypnotic effects via binding to the adenosine receptor. The current study was taken to investigate the metabolic pathway of YZG-331 as well as species-specific differences in vitro. YZG-331 was reduced by 14, 11, 6, 46, and 11% within 120 min incubation in human, monkey, dog, rat, and mouse liver microsomes (LMs), respectively. However, YZG-331 was stable in human, monkey, dog, rat, and mouse liver cytoplasm. In addition, YZG-331 was unstable in rat or mouse gut microbiota with more than 50% of prototype drug degraded within 120 min incubation. Interestingly, the systemic exposure of M2 and M3 in rats and mice treated with antibiotics were significantly decreased in the pseudo germ-free group. YZG-331 could be metabolized in rat and human liver under the catalysis of CYP enzymes, and the metabolism showed species variation. In addition, 3 phase I metabolites were identified via hydroxyl (M1), hydrolysis (M2), or hydrolysis/ hydroxyl (M3) pathway. Flavin-containing monooxygenase 1 (FMO1) and FMO3 participated in the conversion of YZG-331 in rat LMs. Nevertheless, YZG-331 expressed stability with recombinant human FMOs, which further confirmed the species variation in the metabolism. Overall, these studies suggested that YZG-331 is not stable in LMs and gut microbiota. CYP450 enzymes and FMOs mediated the metabolism of YZG-331, and the metabolic pathway showed species difference. Special attention must be paid when extrapolating data from other species to humans. 
546 |a EN 
690 |a YZG-331 
690 |a metabolism 
690 |a CYP450 
690 |a FMOs 
690 |a species variation 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 8 (2017) 
787 0 |n http://journal.frontiersin.org/article/10.3389/fphar.2017.00527/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/2f5bea363c0944f0a0bcc70d9a446925  |z Connect to this object online.